Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart

Background Patients with diabetes mellitus (DM) and coronary artery disease (CAD) have a poor prognosis. Underutilization and reduced efficacy of evidence-based medications (EBM) or revascularization are among suggested explanations. This report compares the impact of EBM and revascularization on mortality and cardiovascular events (CVE = mortality, myocardial infarction or stroke) in CAD patients with and without DM. Design Between February 2003 and January 2004 the Euro Heart Survey on Diabetes and the Heart recruited patients with CAD at 110 centers in 25 European countries. The patients were followed with respect to one-year CVE. Methods The study population included a total of 3488 patients: 2063 (59%) in the non-DM and 1425 (41%) in the DM group. EBM was defined as the combined use of renin-angiotensin-aldosterone system inhibitors, β blockers, antiplatelets and statins while revascularization comprised thrombolysis, percutaneous coronary intervention or coronary artery bypass grafting. Results Of the eligible patients, 44% with DM and 43% of those without DM received EBM, while 34 and 40% were revascularized. In patients with DM both EBM (0.37, 95% confidence interval (CI), 0.20–0.67, P = 0.001) and revascularization (0.72, 95% CI, 0.39–1.32, P = 0.275) had an independent protective effect as regards one-year mortality and as regards CVE (0.61, 95% CI, 0.40–0.91, P = 0.015 and 0.61, 95% CI, 0.39–0.95, P = 0.025, respectively) in patients with DM compared with the impact of these two approaches in those without DM. Conclusion The systematic use of EBM and revascularization has a highly rewarding, favorable impact on one-year prognosis of DM patients with CAD.

[1]  L. V. Van Gaal,et al.  Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. , 2007, European heart journal.

[2]  L. Rydén,et al.  Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[3]  L. Rydén,et al.  Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.

[4]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[5]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[6]  D. Bacquer,et al.  Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.

[7]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[8]  O. Schnell,et al.  Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[9]  Oliver Schnell,et al.  Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry. , 2004, Diabetes care.

[10]  R. Schiele,et al.  Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study , 2003, Acta Diabetologica.

[11]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[12]  K. Malmberg,et al.  Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. , 2003, European heart journal.

[13]  R. Collins,et al.  Heart Protection Study , 2003, The Lancet.

[14]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[15]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[16]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[17]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[18]  M. Marre,et al.  Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. , 2000, Diabetes care.

[19]  W. Koenig,et al.  The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? , 2000, Diabetologia.

[20]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[21]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[22]  M. Harris,et al.  Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.

[23]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[24]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[25]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[26]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[27]  L. Rydén,et al.  Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. , 1997, Cardiovascular research.

[28]  U. Goldbourt,et al.  Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. , 1996, The American journal of cardiology.

[29]  Fibrinolytic Therapy Trialists' Collaborative Group.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.

[30]  Fibrinolytictherapytrialistsf.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[31]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[32]  Bengt Jönsson,et al.  [Guidelines on diabetes, pre-diabetes, and cardiovascular diseases]. , 2007, Revista espanola de cardiologia.

[33]  Michael Miller.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[34]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .